FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Meeting on Kidney Transplant Rejection Drugs

Federal Register notice: FDA plans an 11/9 public meeting entitled Endpoints and Trial Designs to Advance Drug Development in Kidney Transplantation....

latest-news-card-1
Human Drugs

Danco Seeks High Court Abortion Drug Review

Abortion drug distributor Danco Laboratories petitions the U.S. Supreme Court to review last months decision by the Fifth Circuit Court of Appeals tha...

Human Factors Engineering Q&A Guidance

FDA publishes a guidance with questions and answers on applying human factors engineering principles in developing combination drug products.

latest-news-card-1
Human Drugs

Suggestions for ICH Good Clinical Practice Guideline

Four stakeholder groups suggest revisions to an FDA publication of the ICH E6(R3) good clinical practice guideline.

latest-news-card-1
Medical Devices

ISO 10993-1 Clarifying Guidance

FDA publishes a guidance clarifying and updating information on using ISO 10993-1 in preparing medical device submissions to FDA.

latest-news-card-1
Human Drugs

No Marketing of Same Rx and OTC Drugs: Reps

A bipartisan group of three House members asks CDER to remove the simultaneous marketing provision from a proposed rule on Rx to OTC drug switches.

latest-news-card-1
Medical Devices

Philips $615 Million Settlement Over Faulty Devices

Philips Respironics announces it has set aside $615 million under an agreement to resolve all economic loss claims in a class action lawsuit related t...

latest-news-card-1
Human Drugs

Guide on Endogenous Cushings Syndrome

FDA releases a draft guidance entitled Endogenous Cushings Syndrome: Developing Drugs for Treatment.

latest-news-card-1
Human Drugs

Janssen Stops Macitentan Phase 3 Study

Janssen Pharmaceutical discontines, due to futility, its Phase 3 MACiTEPH study evaluating macitentan 75 mg in patients with chronic thromboembolic pu...

latest-news-card-1
Human Drugs

CymaBay Therapeutics Plans NDA for Seladelpar

CymaBay Therapeutics says it will seek FDA approval for seladelpar for treating adult patients with primary biliary cholangitis after reporting Phase ...